Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Oct 15 02:23PM ET
41.49
Dollar change
-2.10
Percentage change
-4.81
%
Index- P/E- EPS (ttm)-18.39 Insider Own80.47% Shs Outstand6.50M Perf Week16.53%
Market Cap269.65M Forward P/E- EPS next Y-10.02 Insider Trans0.00% Shs Float1.27M Perf Month-35.49%
Income-119.58M PEG- EPS next Q-2.10 Inst Own31.52% Short Float14.97% Perf Quarter219.12%
Sales0.00M P/S- EPS this Y1.12% Inst Trans175.77% Short Ratio0.77 Perf Half Y301.60%
Book/sh29.98 P/B1.38 EPS next Y0.03% ROA-34.04% Short Interest0.19M Perf Year462.13%
Cash/sh22.86 P/C1.81 EPS next 5Y- ROE-48.65% 52W Range6.07 - 92.00 Perf YTD444.42%
Dividend Est.- P/FCF- EPS past 5Y-120.38% ROI-42.86% 52W High-54.91% Beta1.60
Dividend TTM- Quick Ratio15.06 Sales past 5Y-25.00% Gross Margin- 52W Low583.44% ATR (14)6.73
Dividend Ex-Date- Current Ratio15.06 EPS Y/Y TTM35.73% Oper. Margin0.00% RSI (14)46.26 Volatility15.95% 15.05%
Employees49 Debt/Eq0.44 Sales Y/Y TTM- Profit Margin- Recom2.00 Target Price103.67
Option/ShortNo / Yes LT Debt/Eq0.43 EPS Q/Q20.07% Payout- Rel Volume0.42 Prev Close43.58
Sales Surprise- EPS Surprise23.15% Sales Q/Q- EarningsAug 13 AMC Avg Volume246.30K Price41.49
SMA20-24.31% SMA5021.17% SMA200146.74% Trades Volume79,041 Change-4.81%
Date Action Analyst Rating Change Price Target Change
Apr-12-24Downgrade Jefferies Buy → Hold $5 → $11
Nov-01-22Downgrade Truist Buy → Hold $16 → $6
Nov-01-22Downgrade Cowen Outperform → Market Perform
Aug-13-21Initiated Robert W. Baird Outperform $34
Apr-13-21Initiated Truist Buy $32
Apr-13-21Initiated Morgan Stanley Equal-Weight $24
Apr-13-21Initiated Cowen Outperform
Sep-27-24 09:43PM
07:03PM
Sep-25-24 04:56AM
Sep-17-24 04:24AM
Sep-16-24 06:00AM
04:56AM Loading…
Sep-14-24 04:56AM
Aug-13-24 10:53PM
05:00PM
Aug-01-24 06:00AM
Jul-12-24 07:41AM
May-10-24 01:54PM
07:00AM
Mar-27-24 12:00PM
Mar-21-24 10:52PM
05:00PM
12:28PM Loading…
Jan-18-24 12:28PM
Jan-16-24 08:00AM
Dec-13-23 10:52AM
10:51AM
Dec-05-23 05:00PM
Nov-13-23 05:00PM
Nov-06-23 07:00AM
Aug-31-23 09:35AM
Aug-14-23 07:00AM
Jun-26-23 04:38PM
May-11-23 07:00AM
Mar-31-23 07:00AM
Mar-22-23 07:57AM
Feb-17-23 07:04AM
Jan-31-23 05:00PM
12:30PM Loading…
Jan-09-23 12:30PM
07:00AM
Dec-13-22 09:35AM
Dec-09-22 09:35AM
Dec-08-22 11:04AM
07:00AM
Nov-14-22 04:07PM
Nov-08-22 07:00AM
Oct-31-22 10:40AM
08:52AM
07:00AM
Oct-18-22 07:00AM
Sep-19-22 07:20AM
Sep-09-22 07:00AM
Sep-06-22 07:00AM
Aug-12-22 07:00AM
Jul-12-22 08:21AM
Jul-11-22 05:28PM
May-27-22 07:00AM
May-18-22 07:00AM
May-16-22 07:00AM
Mar-07-22 07:00AM
Mar-02-22 07:00AM
Nov-15-21 07:00AM
07:00AM
Nov-10-21 11:28AM
Nov-08-21 08:05AM
Sep-16-21 07:00AM
Sep-15-21 04:27PM
Sep-13-21 07:00AM
Sep-02-21 07:00AM
Aug-12-21 07:00AM
Jul-19-21 02:34PM
Jun-21-21 10:06AM
Jun-01-21 07:00AM
May-13-21 07:00AM
Apr-29-21 08:45AM
Apr-27-21 07:00AM
Apr-12-21 07:18AM
Mar-23-21 05:00PM
Mar-19-21 04:25PM
Mar-18-21 08:26PM
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.